REG - Societe Generale SA Takeda Pharma.Co.Ltd - Form 8.3 - Takeda Pharmaceutical CO LTD
RNS Number : 6771ASociete Generale SA13 September 2018FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser:
Société Générale S.A.
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree
Takeda Pharmaceutical CO LTD
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:
For an opening position disclosure, state the latest practicable date prior to the disclosure
12/09/2018
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
YES: Shire PLC
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security:
Ordinary
Interests
Short positions
Number
%
Number
%
(1) Relevant securities owned and/or controlled:
2,596,328
0.33
6,185,550
0.79
(2) Cash-settled derivatives:
5,259,342
0.67
2,026
0.00
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
121,500
0.02
0
0.00
TOTAL:
7,977,170
1.02
6,187,576
0.79
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security
Purchase/sale
Number of securities
Price per unit
JPY
Ordinary
Purchase
900
4560
Ordinary
Purchase
400
4570
Ordinary
Purchase
1,000
4568
Ordinary
Purchase
500
4569
Ordinary
Purchase
100
4564
Ordinary
Purchase
100
4574
Ordinary
Purchase
1,000
4576
Ordinary
Purchase
300
4535
Ordinary
Purchase
300
4559
Ordinary
Purchase
1,400
4575
Ordinary
Purchase
1,000
4556
Ordinary
Purchase
1,000
4559
Ordinary
Purchase
500
4564
Ordinary
Purchase
100
4566
Ordinary
Purchase
1,000
4534
Ordinary
Purchase
700
4535
Ordinary
Purchase
800
4562
Ordinary
Purchase
1,000
4561
Ordinary
Purchase
1,000
4561
Ordinary
Purchase
500
4553
Ordinary
Purchase
1,000
4561
Ordinary
Purchase
1,000
4535
Ordinary
Purchase
400
4533
Ordinary
Purchase
100
4549
Ordinary
Purchase
100
4550
Ordinary
Purchase
1,000
4562
Ordinary
Purchase
1,000
4561
Ordinary
Purchase
700
4562
Ordinary
Purchase
600
4551
Ordinary
Purchase
1,200
4561
Ordinary
Purchase
100
4566
Ordinary
Purchase
100
4555
Ordinary
Purchase
1,000
4556
Ordinary
Purchase
200
4561
Ordinary
Purchase
200
4536
Ordinary
Purchase
100
4553
Ordinary
Purchase
1,400
4553
Ordinary
Purchase
800
4560
Ordinary
Purchase
300
4554
Ordinary
Purchase
100
4555
Ordinary
Purchase
200
4574
Ordinary
Purchase
1,000
4559
Ordinary
Purchase
300
4556
Ordinary
Purchase
200
4557
Ordinary
Purchase
1,800
4558
Ordinary
Purchase
200
4534
Ordinary
Purchase
200
4565
Ordinary
Purchase
900
4562
Ordinary
Purchase
900
4535
Ordinary
Purchase
1,000
4570
Ordinary
Purchase
400
4577
Ordinary
Purchase
900
4548
Ordinary
Purchase
400
4581
Ordinary
Purchase
100
4535
Ordinary
Purchase
300
4584
Ordinary
Purchase
400
4548
Ordinary
Purchase
1,000
4578
Ordinary
Purchase
100
4555
Ordinary
Purchase
1,000
4535
Ordinary
Purchase
1,000
4576
Ordinary
Purchase
1,000
4545
Ordinary
Purchase
800
4555
Ordinary
Purchase
100
4567
Ordinary
Purchase
100
4534
Ordinary
Purchase
100
4560.5
Ordinary
Purchase
200
4556
Ordinary
Purchase
100
4552.5
Ordinary
Purchase
100
4563.5
Ordinary
Purchase
200
4533.5
Ordinary
Purchase
100
4541
Ordinary
Purchase
200
4567
Ordinary
Purchase
200
4567
Ordinary
Purchase
200
4575
Ordinary
Purchase
200
4544
Ordinary
Purchase
200
4584
Ordinary
Purchase
100
4570
Ordinary
Purchase
200
4571
Ordinary
Purchase
600
4572
Ordinary
Purchase
500
4570
Ordinary
Purchase
600
4562
Ordinary
Purchase
600
4573
Ordinary
Purchase
700
4572
Ordinary
Purchase
700
4572
Ordinary
Purchase
600
4571
Ordinary
Purchase
100
4570
Ordinary
Purchase
700
4565
Ordinary
Purchase
300
4560
Ordinary
Purchase
600
4568
Ordinary
Purchase
300
4566
Ordinary
Purchase
100
4565
Ordinary
Purchase
500
4566
Ordinary
Purchase
2,200
4576
Ordinary
Purchase
200
4566
Ordinary
Purchase
300
4565
Ordinary
Purchase
1,500
4575
Ordinary
Purchase
51,600
4564
Ordinary
Purchase
200
4575
Ordinary
Purchase
13,900
4574
Ordinary
Purchase
74
4600
Ordinary
Purchase
100
4572
Ordinary
Purchase
100
4572
Ordinary
Sale
1,000
4573
Ordinary
Sale
800
4575
Ordinary
Sale
13,900
4574
Ordinary
Sale
50,000
4574
Ordinary
Sale
20,000
4571
Ordinary
Sale
100
4565
Ordinary
Sale
100
4552
Ordinary
Sale
100
4561
Ordinary
Sale
2,500
4574
Ordinary
Sale
300
4572
Ordinary
Sale
4,700
4574
Ordinary
Sale
30,000
4574
Ordinary
Sale
20,000
4574
Ordinary
Sale
400
4571
Ordinary
Sale
400
4572
Ordinary
Sale
500
4577
Ordinary
Sale
600
4581
Ordinary
Sale
100
4562
Ordinary
Sale
1,400
4561
Ordinary
Sale
300
4560
Ordinary
Sale
2,000
4561
Ordinary
Sale
1,100
4541
Ordinary
Sale
1,500
4560
Ordinary
Sale
1,600
4554
Ordinary
Sale
100
4581
Ordinary
Sale
200
4562
Ordinary
Sale
100
4561
Ordinary
Sale
1,200
4561
Ordinary
Sale
600
4558
Ordinary
Sale
1,000
4557
Ordinary
Sale
800
4561
Ordinary
Sale
300
4552
Ordinary
Sale
300
4565
Ordinary
Sale
100
4557
Ordinary
Sale
800
4560
Ordinary
Sale
100
4554
Ordinary
Sale
800
4533
Ordinary
Sale
100
4557
Ordinary
Sale
300
4558
Ordinary
Sale
100
4562
Ordinary
Sale
400
4556
Ordinary
Sale
100
4543
Ordinary
Sale
100
4559
Ordinary
Sale
1,300
4562
Ordinary
Sale
1,400
4534
Ordinary
Sale
100
4571
Ordinary
Sale
1,100
4575
Ordinary
Sale
200
4573
Ordinary
Sale
200
4534
Ordinary
Sale
1,700
4552
Ordinary
Sale
100
4553
Ordinary
Sale
600
4533
Ordinary
Sale
100
4553
Ordinary
Sale
400
4575
Ordinary
Sale
1,700
4553
Ordinary
Sale
100
4575
Ordinary
Sale
1,500
4576
Ordinary
Sale
200
4573
Ordinary
Sale
300
4573
Ordinary
Sale
400
4571
Ordinary
Sale
100
4570
Ordinary
Sale
800
4570
Ordinary
Sale
500
4557
Ordinary
Sale
1,100
4574
Ordinary
Sale
800
4561
Ordinary
Sale
100
4551
Ordinary
Sale
300
4552
Ordinary
Sale
1,500
4534
Ordinary
Sale
600
4533
Ordinary
Sale
200
4564
Ordinary
Sale
200
4563
Ordinary
Sale
500
4563
Ordinary
Sale
500
4563
Ordinary
Sale
100
4549
Ordinary
Sale
600
4544
Ordinary
Sale
200
4560
Ordinary
Sale
100
4545
Ordinary
Sale
1,900
4557
Ordinary
Sale
200
4550
Ordinary
Sale
1,400
4549
Ordinary
Sale
500
4549
Ordinary
Sale
100
4586
Ordinary
Sale
200
4584
Ordinary
Sale
300
4550
Ordinary
Sale
300
4574
Ordinary
Sale
10,200
4600
Ordinary
Sale
2,200
4574
Ordinary
Sale
174
4433
Ordinary
Sale
75
4576
Ordinary
Sale
100
4572
Total Purchases
118,474
Total Sales
198,149
(b) Cash-settled derivative transactions
Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit JPY
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit JPY
(ii) Exercise
Class of relevant security
Product description
e.g. call option
Exercising/ exercised against
Number of securities
Exercise price per unit JPY
(d) Other dealings (including subscribing for new securities)
Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable) JPY
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached?
YES
Date of disclosure:
13/09/2018
Contact name:
Olivier Vero
Telephone number:
+44 20 7676 6969
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk
SUPPLEMENTAL FORM 8 (OPEN POSITIONS)
DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.
Note 5(i) on Rule 8 of the Takeover Code (the "Code")
1. KEY INFORMATION
Full name of person making disclosure:
SOCIETE GENERALE SA
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:
Takeda Pharmaceutical CO LTD
2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
Class of relevant security
Product description e.g. call option
Written or purchased
Number of securities to which option or derivative relates
Exercise price per unit
Type
Expiry date
JPY
e.g. American, European etc.
Ordinary
OTC put-option
Sale
15,700
4707
European options
14/12/2018
Ordinary
OTC put-option
Sale
30,000
5075.10
European options
14/12/2018
Ordinary
OTC put-option
Sale
29,600
5073.65
European options
14/12/2018
Ordinary
OTC put-option
Sale
15,500
4491.40
European options
14/12/2018
Ordinary
OTC put-option
Sale
30,700
4533.90
European options
14/12/2018
3. AGREEMENTS TO PURCHASE OR SELL ETC.
Full details should be given so that the nature of the interest or position can be fully understood:
It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.
The currency of all prices and other monetary amounts should be stated.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDRETGGURABUPRURW
Recent news on Takeda Pharmaceutical Co
See all newsREG - Malin Corp PLC - Malin Announces 2021 Full Year Results
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Confirmation of post-offer intention statements
AnnouncementREG - Morgan Stanley&CoLLC Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Statement re Applicable Exchange Rate
AnnouncementREG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda
Announcement